» Articles » PMID: 35365860

Persistent Symptoms of Fatigue, Neuropathy and Role-functioning Impairment Among Indolent Non-Hodgkin Lymphoma Survivors: A longitudinal PROFILES Registry Study

Abstract

Little is known about the long-term health-related quality of life (HRQoL) and persistence of symptoms among patients with indolent non-Hodgkin lymphoma (iNHL). This large population-based longitudinal study therefore investigated the long-term HRQoL and persistence of symptoms and identified associated sociodemographic, clinical and psychological factors. Patients diagnosed between 1999 and 2014 and four or more months after diagnosis were invited to participate in a longitudinal survey. Sociodemographic and clinical data were obtained from the Netherlands Cancer Registry. The EORTC QLQ-C30 and CLL-16 were completed by 669 patients (74% response rate). Patients completed on average four questionnaires. Primary treatment was active surveillance (52%), systemic therapy (31%) or radiotherapy (13%). Respectively, 36% reported persistent fatigue, 33% persistent neuropathy and 25% persistent role-functioning impairment. This was 2-3 times higher than in the age- and sex-matched normative population. Up to 10 years after diagnosis, scores remained relatively stable without clinically relevant changes. Comorbidities, psychological distress, shorter time since diagnosis, systemic therapy, younger age, education level and having no partner were associated with worse outcomes (all ps < 0.05). Up to a third of patients with iNHL experience long-term persistent symptoms which do not improve over time. Early recognition of symptoms will help in providing tailored supportive care for those in need.

Citing Articles

Diffuse large B-cell lymphoma presenting as acute lumbosacral plexopathy with persistent lower back pain and fatigability.

Ghosh R, Leon-Ruiz M, Mondal A, Dubey S, Benito-Leon J J Family Med Prim Care. 2025; 14(1):466-469.

PMID: 39989582 PMC: 11844978. DOI: 10.4103/jfmpc.jfmpc_759_24.


Adverse health outcomes and health-related quality of life (HRQoL) among long-term adolescent and young adult (AYA) brain tumour survivors: results from the population-based SURVAYA study.

Angoumis K, Padilla C, Kouwenhoven M, Bijlsma R, Kaal S, Tromp J Support Care Cancer. 2025; 33(2):95.

PMID: 39808329 PMC: 11732903. DOI: 10.1007/s00520-025-09155-9.


Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.

Efficace F, Sparano F, Breccia M, Greco C, Carluccio P, Borlenghi E Ann Hematol. 2024; 103(12):5341-5349.

PMID: 39438322 DOI: 10.1007/s00277-024-06038-7.


Health care utilization up to 11 years after diagnosis among patients with a hematologic malignancy and its association with socioeconomic position.

Ekels A, van de Poll-Franse L, Issa D, Oosterveld M, van der Griend R, Hoogendoorn M J Cancer Surviv. 2024; .

PMID: 39287915 DOI: 10.1007/s11764-024-01676-2.


Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.

Ekels A, van de Poll-Franse L, Issa D, Hoogendoorn M, Nijziel M, Koster A Ann Hematol. 2024; 103(12):5511-5525.

PMID: 39279019 DOI: 10.1007/s00277-024-06006-1.